Alterations in the expression of α6β4 integrin and p21/WAF1/Cip1 in N- nitrosomethylbenzylamine-induced rat esophageal tumorigenesis

Molecular Carcinogenesis

Volumn 21, Issue 3, 1998, Pages 185-193

  Khare, Leena ^a   Sabourin, Carol L K ^a   DeYoung, Barry R ^a   Wagner, Beth A ^b   Stoner, Gary D ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Esophageal epithelium; Integrins; Rat; Squamous cell carcinoma

Indexed keywords

INTEGRIN; N BENZYL N METHYLNITROSAMINE; PROTEIN P21; ALPHA6BETA4 INTEGRIN; CARCINOGEN; CDKN1A PROTEIN, RAT; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; DIMETHYLNITROSAMINE; DRUG DERIVATIVE; MEMBRANE ANTIGEN; MESSENGER RNA; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; ESOPHAGUS CARCINOMA; GENE EXPRESSION REGULATION; MALE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED DISORDER; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; ESOPHAGUS; ESOPHAGUS TUMOR; FISCHER 344 RAT; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSCRIPTION; METABOLISM; POLYMERASE CHAIN REACTION; PRECANCER;

ANIMALS; ANTIGENS, SURFACE; BLOTTING, NORTHERN; CARCINOGENS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DIMETHYLNITROSAMINE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FLUORESCENT ANTIBODY TECHNIQUE; INTEGRIN ALPHA6BETA4; INTEGRINS; MALE; POLYMERASE CHAIN REACTION; PRECANCEROUS CONDITIONS; RATS; RATS, INBRED F344; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 0031594820     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199803)21:3<185::AID-MC6>3.0.CO;2-L     Document Type: Article

References (53)

1. Hynes RO. Integrins: Versatility, modulation, and signalling in cell adhesion. Cell 69:11-25, 1992.
2. Watt FM, Kubler MD, Hotchin NA, Nicholson LJ, Adams JC. Regulation of keratinocyte terminal differentiation by integrin-extracellular matrix interactions. J Cell Sci 106:175-182, 1993.
3. Garrod DR. Desmosomes and hemidesmosomes. Curr Opin Cell Biol 5:30-40, 1993.
4. Stepp MA, Spurr-Michaud S, Tisdale A, Elwell J, Gipson IK, α6β4 integrin heterodimer is a component of hemidesmosomes. Proc Natl Acad Sci USA 87:8970-8974, 1990.
5. Sonnenberg A, Calafat J, Janssen H, et al. Integrin α6β4 complex is located in hemidesmosomes suggesting a major role in epidermal cell-basement membrane adhesion. J Cell Biol 113:907-917, 1991.
6. Spinardi L, Einheber S, Cullen T, Milner TA, Giancotti FG. A recombinant tail-less integrin β4 subunit disrupts hemidesmosomes but does not suppress α6β4-mediated cell adhesion to laminins. J Cell Biol 129:473-487, 1995.
7. Clarke AS, Lotz MM, Chao C, Mercurio AM. Activation of the p21 pathway of growth arrest and apoptosis of the β4 integrin cytoplasmic domain. J Cell Biol 270:22673-22676, 1995.
8. Halevy O, Novitch BG, Spicer DB, et al. Correlation of terminal cell cycle arrest of skeletal muscles with induction of p21 by Myo D. Science 267:1018-1021, 1995.
9. Cip1 in muscle and other terminally differentiating cells. Science 267:1024-1027, 1995.
10. Kim SY, Bachman NJ, Nair TS, et al. β4 integrin transfection of UM-UC-2 (human bladder carcinoma) cells: Stable expression of a spontaneous cytoplasmic truncation mutant with rapid loss of clones expressing intact β4. Cancer Res 57:38-42, 1997.
11. Sager R, Anisowitz A, Neveu M, Liang P, Sotiropoulou G. Identification by differential display of alpha 6 integrin as a candidate tumor suppressor gene. FASEB J 7:964-970, 1993.
12. Jones J, Sugiyama M, Watt FM, Speight PM. Integrin expression in normal, hyperplastic, dysplastic, and malignant oral epithelium. J Pathol 169:235-243, 1993.
13. Downer CS, Watt FM, Speight PM. Loss of α6 and β4 integrin subunits coincides with loss of basement membrane components in oral squamous cell carcinomas. J Pathol 171:183-190, 1993.
14. Sugiyama M, Speight PM, Prime SS, Watt FM. Comparison of integrin expression and terminal differentiation capacity in cell lines derived from oral squamous cell carcinomas. Carcinogenesis 10:2171-2176, 1993.
15. Savoia P, Trusolino L, Pepino E, Cremona O, Marchisio PC. Expression and topography of integrins and basement membrane proteins in epidermal carcinomas: Basal but not squamous cell carcinomas display loss of α6β4 and BM-600/Nicein. J Invest Dermatol 101:352-357, 1993.
16. Skubitz APN, Bast RC Jr, Wayner EA, Letourneau PC, Wilke MS. Expression of α6 and β4 integrins in serous ovarian carcinoma correlates with expression of the basement membrane protein laminin. Am J Pathol 148:1445-1461, 1996.
17. Jones JL, Critchley DR, Walker RA. Alteration of stromal protein and integrin expression in breast-A marker of premalignant change. J Pathol 167:399-406, 1992.
18. Pignatelli M, Cardillo MR, Hanby A, Stamp GWH. Integrins and their accessory adhesion molecules in mammary carcinomas: Loss of polarization in poorly differentiated tumors. Hum Pathol 23:1159-1166, 1992.
19. Knox JD, Cress AE, Clark V, et al. Differential expression of extracellular matrix molecules and the α6-integrins in the normal and neoplastic prostate. Am J Pathol 115:167-174, 1994.
20. Liebert M, Washington R, Wedemeyer G, Carey TE, Grossman HB. Loss of co-localization of α6β4 integrin and collagen VII in bladder cancer. Am J Pathol 144:787-795, 1994.
21. Lessey BA, Albeida S, Buck CA, et al. Distribution of integrin cell adhesion molecules in endometrial cancer. Am J Pathol 146:717-726, 1995.
22. Druckrey H. Organospecific carcinogenesis in the digestive tract. In: Nakahara W, Takayama S, Sugimara T, Odashima S (eds). Topics in Chemical Carcinogenesis. University Park Press, Baltimore, 1972, pp. 73-101.
23. Lijinsky W, Saavedra JE, Rueber MD, Singer SS. Esophageal carcinogenesis in Fischer F344 rats by nitrosomethylamines substituted in the ethyl group. J Natl Cancer Inst 68:681-684, 1980.
24. Lijinsky W, Reuber MD. Carcinogenicity in rats of nitrosomethylethylamines labelled with deuterium in several positions. Cancer Res 40:19-21, 1980.
25. Mandal S, Stoner GD. Inhibition of N-nitrosobenzylmethylamine-induced esophageal tumorigenesis in rats by ellagic acid. Carcinogenesis 11:55-61, 1990.
26. Wang Y, You M, Reynolds SH, Stoner GD, Anderson MW. Mutational activation of the cellular Harvey ras oncogene in rat esophageal papillomas induced by methylbenzylnitrosamine. Cancer Res 50:1591-1595, 1990.
27. Daniel EM, Stoner GD. The effects of ellagic acid and 13-cis-retinoic acid on N-nitrosobenzylmethylamine carcinogenesis in the rat esophagus. Cancer Lett 56:117-124, 1991.
28. Stoner GD, Morrissey DT, Heur Y-H, Daniel EM, Galati AJ, Wagner SA. Inhibitory effects of phenethyl isothiocyanate on N-nitrosobenzylmethylamine carcinogenesis in the rat esophagus. Cancer Res 51:2063-2068, 1991.
29. Morse MA, Zu H, Galati AJ, Schmidt CJ, Stoner GD. Dose-related inhibition by dietary phenethyl isothiocyanate on esophageal tumorigenesis and DNA methylation induced by N-nitrosobenzylmethylamine in rats. Cancer Lett 72:103-110, 1993.
30. Siglin JC, Khare L, Stoner GD. Evaluation of dose and treatment duration on the esophageal tumorigenicity of N-nitrosomethylbenzylamine in rats. Carcinogenesis 16:259-265, 1995.
31. Siglin JC, Barch DH, Stoner GD. Effects of dietary phenethyl isothiocyanate, ellagic acid, sulindac, and calcium on the induction and progression of N-nitrosomethylbenzylamine-induced esophageal carcinogenesis in rats. Carcinogenesis 16:1101-1106, 1995.
32. Wilkinson JT, Morse MA, Kresty LA, Stoner GD. Effects of alkyl chain length on inhibition of N-nitrosomethylbenzylamine-induced esophageal tumorigenesis and DNA methylation by isothiocyanates. Carcinogenesis 16:1011-1015, 1995.
33. Wang Q-S, Sabourin CLK, Bijur GN, Robertson FM, Stoner GD. Alterations in transforming growth factor-α and epidermal growth factor receptor expression during rat esophageal tumorigenesis. Mol Carcinog 15:144-153, 1996.
34. Wang D, Weghorst CM, Calvert RJ, Stoner GD. Mutations in the p53 tumor suppressor gene in rat esophageal papillomas induced by N-nitrosomethylbenzylamine. Carcinogenesis 17:625-630, 1996.
35. Wang Q-S, Sabourin CLK, Wang H, Stoner GD. Overexpression of cyclin D1 andcyclin E in N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis. Carcinogenesis 17:1583-1588, 1996.
36. Wang Q-S, Sabourin CLK, Kresty LA, Stoner GD. Dysregulation of transforming growth factor-β1 expression in N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis. Int J Oncol 9:473-479, 1996.
37. Feltri L, Scherer SS, Nemni R, et al. β4 integrin expression in myelinating Schwann cells is polarized, developmentally regulated, and axonally dependent. Development 120:1287-1301, 1994.
38. Feltri L, Arona M, Scherer SS, Wrabetz L. Cloning and sequence of the cDNA encoding the β4 integrin subunit in rat peripheral nerve. Gene 186:299-304, 1997.
39. El-Deiry WS, Tokino T, Waldman T, et al. Topological control of p21/WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 55:2910-2919, 1995.
40. Jansen JG, Vrieling H, van Zeeland AA, Mohn GR. The gene encoding hypoxanthine-guanine phosphoribosyltransferase as target for mutational analysis: PCR cloning and sequencing of the cDNA from the rat. Mutat Res 266:105-116, 1992.
41. Tannenbaum T, Belanger AJ, Glick AB, Tamura R, Quaranta V, Yuspa SH. A splice variant of α6 integrin is associated with malignant conversion in mouse skin tumorigenesis. Proc Natl Acad Sci USA 92:7041-7045, 1995.
42. Waf1. Cancer Res 55:4536-4539, 1995.
43. waf is contained in its N-terminal half (half-WAF). Oncogene 11:393-395, 1995.
44. Ruggeri BA, Huang L, Berger D, et al. Molecular pathology of primary and metastatic ductal pancreatic lesions: Analysis of mutations and expression of p53, mdm-2, and p21/ Waf-1 genes in sporadic and familial lesions. Cancer 79:700-716, 1997.
45. Aur G, Einhorn N, Nilsson B, Silfversward C, Sjovall K. Biological malignancy grading in early-stage ovarian carcinoma. Acta Oncol 35(suppl 8):93-98, 1996.
46. Tannenbaum T, Yuspa SH, Grover A, et al. Extracellular matrix receptor and mouse skin carcinogenesis: Altered expression linked to appearance of early markers of tumor progression. Cancer Res 52:2966-2976, 1992.
47. De Melker AA, Sonnenberg A. The role of the cytoplasmic domain of α6 integrin in the assembly and function of α6β1 and α6β4. Eur J Biochem 241:254-264, 1996.
48. Cano A, Gamallo C, Kemp CJ, et al. Expression pattern of the cell adhesion molecules E-cadherin, P-cadherin, and α6β4 integrin is altered in premalignant skin tumors of p53-deficient mice. Int J Cancer 65:254-262, 1996.
49. Tannenbaum T, Weiner AK, Belanger AJ, Glick AB, Hennings H, Yuspa SH. The suprabasal expression of α6β4 integrin is associated with a high risk for malignant progression in mouse skin carcinogenesis. Cancer Res 53:4803-4810, 1993.
50. Natali PG, Nicotra MR, Botti C, Mottolese M, Bigotti A, Segatto O. Changes in expression of α6/β4 integrin heterodimer in primary and metastatic breast cancer. Br J Cancer 66:318-322, 1992.
51. Solberg S, Ryynanen J, Olsen DR, Ditto J. Transforming growth factor-β upregulates the expression of the genes for β4 integrin and bullous pemphigoid antigens (BPAG1 and BPAG2) in normal and transformed human keratinocytes. J Invest Dermatol 99:409-414, 1992.
52. Huang S, Chakrabarty S. Regulation of fibronectin and laminin receptor expression, fibronectin and laminin secretion in human colon cancer cells by transforming growth factor-β1. Int J Cancer 57:742-746, 1994.
53. HER2 oncoprotein and mediates growth inhibition of breast carcinoma cells. Br J Cancer 74:1427-1433, 1996.